Glaukos Submits US IDE for Clinical Study of iStent Infinite in Refractory Glaucoma

January 5, 2018: By Jon Swedien

Glaukos submitted an investigational device exemption (IDE) application to the US FDA to study its iStent Infinite Trabecular Micro-Bypass System for use in a standalone procedure to reduce elevated intraocular pressure (IOP) in refractory glaucoma patients, the San Clemente, California, company announced Jan. 3.

The iStent Infinite is made up of three heparin-coated titanium stents preloaded into an auto-injection system that allows the surgeon to inject stents around Schlemm’s canal across a span of five to six hours. Once in place, the stents are designed to lower IOP by restoring the natural outflow of aqueous humor, Glaukos said.

In the IDE application, Glaukos proposes to conduct a prospective, multi-center, single-arm clinical trial to evaluate safety and performance of the iStent Infinite in about 65 refractory subjects or subjects on maximally tolerated ocular hypotensive medications. The proposed primary endpoint is a 20 percent or greater reduction in IOP from baseline at 12 months on the same or fewer medications, Glaukos said. The company said it plans to use the trial results as the basis for seeking FDA clearance via a 510(k) submission.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Ivantis Gains US FDA Approval for Hydrus Microstent

US FDA Approves Sun Pharma’s CEQUA for Dry Eye

Regeneron Receives US FDA Approval for 12-Week Eylea Dosing

STAAR, Japan’s Shinjuku LASIK Clinic Sign Multiyear Agreement

Alcon Launches Finesse Sharkskin ILM Forceps

Imprimis’ Q2-2018 Revenues Increase 51 Percent to $10.4 Million

Bausch Health Revenues in Q2-2018 Drop 5 Percent

TearLab’s Q2-2018 Revenues Drop 8.5 Percent to $6.4 Million

DeepMind AI System Accurately Detects Eye Disease in OCT Scans at Moorfields

Study by MIT, Mass Eye and Ear Suggests Glaucoma is Autoimmune Disease

Study Indicates Insulin May Restore Vision in Glaucoma

CHOP Researchers Define Six ROP Indicators

Nicox Initiates Phase II Study of NCX 470 in Open-Angle Glaucoma, Ocular Hypertension

Eyenovia’s Microdose Latanoprost Delivers Drug with Precision, Lowers IOP in Proof-of-Concept Study

Rayner to Launch Sulcoflex Trifocal Toric IOL in September

CMS Allows Medicare Advantage Plans to Apply Step Therapy to Retinal Injections

Glaukos Reports Drug Collaboration with D. Western, Q2-2018 Net Sales Increase of 5 Percent

Allergan Will Co-develop Editas’ CRISPR Genome Editing Candidate for LCA10

Spark Reports Q2-2018 Net Sales of $4.3 Million for Luxturna

Aerie’s Rhopressa Posts $2.4 Million in Net Revenues in Q2-2018

Coming soon

2018 Ophthalmic Laser Report: A Global Market Analysis for 2017 to 2023 (Photocoagulation, Photodisruption, and SLT